Acerus Pharmaceuticals Corporation (ASP) - Financial and Strategic SWOT Analysis Review

Description:
Acerus Pharmaceuticals Corporation (ASP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights
Acerus Pharmaceuticals Corporation (Acerus), formerly Trimel Pharmaceuticals Corporation, is a pharmaceutical company that develops, manufactures, markets and distributes innovative branded products. It focuses on men's and women's health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Acerus's product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is headquartered in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals Corporation Key Recent Developments

Apr 08, 2016: Acerus comments on statement of claim
Apr 05, 2016: Litigation Against Acerus Pharmaceuticals Continues
Mar 24, 2016: Acerus Announces Departure of Dr. Michael Bumby
Mar 09, 2016: Eugene Melnyk Initiates Legal Proceedings Against Acerus Pharmaceuticals, its Chairman, Ihor Ihnatowycz, and Others
Mar 02, 2016: Acerus Reports Fourth Quarter and Full Year 2015 Financial Results

Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Acerus Pharmaceuticals Corporation - Weaknesses
Weakness - Endo’s Prioritization of Analgesic
Weakness - History of Losses

Acerus Pharmaceuticals Corporation - Opportunities
Opportunity - New Agreements
Opportunity - Business Initiative
Opportunity - Approval of Natesto

Acerus Pharmaceuticals Corporation - Threats
Threat - Competitive Pressures
Threat - Contractual Obligations
Threat - Compliance with Regulatory Requirements

Acerus Pharmaceuticals Corporation - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Acerus Pharmaceuticals Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Acerus Pharmaceuticals Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Acerus Pharmaceuticals Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016
Acerus Pharmaceuticals Corporation, Medical Equipment, Deals By Type, 2010 to YTD 2016
Acerus Pharmaceuticals Corporation, Recent Deals Summary

Section 5 – Company’s Recent Developments
Apr 08, 2016: Acerus comments on statement of claim
Apr 05, 2016: Litigation Against Acerus Pharmaceuticals Continues
Mar 24, 2016: Acerus Announces Departure of Dr. Michael Bumby
Mar 09, 2016: Eugene Melnyk Initiates Legal Proceedings Against Acerus Pharmaceuticals, its Chairman, Ihor Ihnatawycz, and Others
Mar 02, 2016: Acerus Reports Fourth Quarter and Full Year 2015 Financial Results
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Acerus Pharmaceuticals Corporation, Ratio Charts
Acerus Pharmaceuticals Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Acerus Pharmaceuticals Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Acerus Pharmaceuticals Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016
Acerus Pharmaceuticals Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3750882/](http://www.researchandmarkets.com/reports/3750882/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Acerus Pharmaceuticals Corporation (ASP) - Financial and Strategic SWOT Analysis Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3750882/">http://www.researchandmarkets.com/reports/3750882/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2GB6O</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 125</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 250</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 375</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>____________________________</td>
<td>Last Name:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td>* ____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp